Literature DB >> 10906724

Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins.

J Schuhmacher1, K Bühner, A Witt-Laido.   

Abstract

This report describes a new method for the determination of protein binding and relative protein binding (ratio of f(u) for different species) for compounds strongly bound to proteins. The method used is based on the distribution of the drug in plasma water, plasma proteins, and blood cells. Incubations were performed in diluted plasma. In diluted plasma, the erythrocyte/plasma distribution was determined with greater precision than in undiluted plasma. Formulae were derived for calculating f(u) in undiluted plasma based on the f(u) values determined in diluted plasma. These formulae are also valid in the event of more than one independent binding site in plasma. All incubations with plasma of different species were performed using rat erythrocyte suspensions, thereby making it possible for relative f(u) values in different species to be calculated without knowing the absolute free fractions. This method avoids the determination of the erythrocyte/buffer distribution in cases where it is sufficient to know relative f(u) values (e.g., exposure comparisons). Relative protein binding can also be quantified for compounds that tend to adsorb to surfaces of vials or test tubes, thus avoiding errors caused by adsorption when quantifying the drug in a protein-free aqueous solution. This method was validated by making comparisons of free fraction values obtained by the method herein described with those obtained by either ultrafiltration or equilibrium dialysis for two compounds that bind predominantly to albumin and another compound that binds to alpha(1)-acid glycoprotein. The results confirm our method produces identical free fractions in comparison with other established techniques. In addition, the range of applications of our method is much wider. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10906724     DOI: 10.1002/1520-6017(200008)89:8<1008::aid-jps5>3.0.co;2-b

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  12 in total

1.  Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).

Authors:  Reiner Frey; Corina Becker; Sigrun Unger; Anja Schmidt; Georg Wensing; Wolfgang Mück
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

2.  Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).

Authors:  Reiner Frey; Corina Becker; Sigrun Unger; Anja Schmidt; Georg Wensing; Wolfgang Mück
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

3.  Riociguat (BAY 63-2521) and aspirin: a randomized, pharmacodynamic, and pharmacokinetic interaction study.

Authors:  Reiner Frey; Michael Reber; Jörn Krätzschmar; Sigrun Unger; Wolfgang Mück; Georg Wensing
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

4.  Biological characterization of novel inhibitors of the gram-positive DNA polymerase IIIC enzyme.

Authors:  Alexander Kuhl; Niels Svenstrup; Christoph Ladel; Michael Otteneder; Annegret Binas; Guido Schiffer; Michael Brands; Thomas Lampe; Karl Ziegelbauer; Helga Rübsamen-Waigmann; Dieter Haebich; Kerstin Ehlert
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

5.  Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys.

Authors:  Bridget L Morse; Jamus G MacGuire; Anthony M Marino; Yue Zhao; Maxine Fox; Yueping Zhang; Hong Shen; W Griffith Humphreys; Punit Marathe; Yurong Lai
Journal:  AAPS J       Date:  2017-10-10       Impact factor: 4.009

6.  Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling.

Authors:  Olaf Weber; Stefan Willmann; Hilmar Bischoff; Volkhart Li; Alexandros Vakalopoulos; Klemens Lustig; Frank-Thorsten Hafner; Roland Heinig; Carsten Schmeck; Klaus Buehner
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

7.  Quantifying Hepatic Enzyme Kinetics of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC, through In Vitro Modeling.

Authors:  Gabriela I Patilea-Vrana; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2019-05-02       Impact factor: 3.922

8.  Tuning polypeptide-based micellar carrier for efficient combination therapy of ErbB2-positive breast cancer.

Authors:  Kruti S Soni; Fan Lei; Swapnil S Desale; Luis A Marky; Samuel M Cohen; Tatiana K Bronich
Journal:  J Control Release       Date:  2017-09-11       Impact factor: 9.776

9.  Pharmacokinetics, protein binding and metabolism of a quinoxaline urea analog as an NF-κB inhibitor in mice and rats by LC-MS/MS.

Authors:  Nagsen Gautam; Sai Praneeth R Bathena; Qianyi Chen; Amarnath Natarajan; Yazen Alnouti
Journal:  Biomed Chromatogr       Date:  2013-03-10       Impact factor: 1.902

10.  Modulation of nonspecific binding in ultrafiltration protein binding studies.

Authors:  Kyoung-Jin Lee; Rachel Mower; Tom Hollenbeck; Jesus Castelo; Nikole Johnson; Perry Gordon; Patrick J Sinko; Kevin Holme; Yong-Hee Lee
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.